Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic use of a sterile aqueous ophthalmic solution

An ophthalmic solution, water-based technology, applied in the direction of organic active ingredients, inorganic inactive ingredients, medical preparations of inactive ingredients, etc.

Active Publication Date: 2018-07-31
CROMA PHARMA GMBH
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are conflicting reports on the effect of chitosan on corneal wound healing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic use of a sterile aqueous ophthalmic solution
  • Therapeutic use of a sterile aqueous ophthalmic solution
  • Therapeutic use of a sterile aqueous ophthalmic solution

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] Example 1: Corneal Wound Healing Model

[0091] The purpose of this experiment was to evaluate the aqueous ophthalmic solution containing 0.1% chitosan-NAC (degree of modification: 209 μM free thiol groups / g polymer) compared to a control substance consisting of phosphate buffered saline (PBS). Whether the solution can speed up the wound healing process. Prepared under inert conditions containing 0.1% (w / w) Aqueous ophthalmic solution of chitosan-NAC. The final pH of the solution was 6.4. Female New Zealand White rabbits (Charles River, Ekrath, Germany) weighing 1.7 kg to 2.5 kg were used in this experiment. Animals were housed in pairs in a controlled environment: artificial circadian rhythm of 12 / 12 hours, room temperature 20°C, humidity 60%. Rabbits were provided with water and standard chow ad libitum. Animals were not started on studies until after a period of at least 2 weeks (to acclimate) after arrival.

[0092] A total of 16 animals were induced with de...

Embodiment 2

[0094] Example 2 The polymer network structure formed on the ocular surface tissue

[0095] Human limbal epithelial cells (HCLE) were incubated at 37°C and 5% CO 2 maintained in serum-free keratinocyte growth medium (Thermo Fisher Scientific), and seeded 1×10 5 cells / well into 24-well plates (equipped with 11 mm cover glass). When the cells reached confluence, they were treated with 0.1% (w / w) chitosan-HCl or 0.1% (w / w) chitosan-NAC (modification degree: 219 μM free thiol groups) diluted in 100 mM borate buffer. pellet / gram of polymer) for 15 minutes. Simultaneously, borate buffer was applied to control cells. Next, the polymer solution was removed and the cells were immediately fixed for scanning electron microscopy (SEM) by adding 2.5% glutaraldehyde in 0.06×PHEM buffer (1×PHEM buffer contained 60 mM PIPES, 25 mM HEPES, 10 mM EGTA and 2 mM MgCl 2 ) for cell fixation. Then, the monolayers were post-fixed in 1% aqueous osmium tetroxide (Agar Scientific, Stansted, UK),...

Embodiment 3

[0097] Example 3 Case Study

[0098] A 57-year-old male patient with extremely severe atopic dermatitis and multiple recurrent herpetic keratitis required urgent penetrating keratoplasty due to perforation. He subsequently developed a post-transplant infection requiring antibiotic control. However, he also suffered from a persistent epithelial defect that did not heal after several months despite several different medications (topical medications: Moxifloxacin (Vigamox) 4× / day, Dexa EDO 2× / day and Vismed once an hour; oral medication: valacyclovir (Valtrex) 1-0-1, mycophenolic acid extended-release tablets (Myfortic) 360mg 2-0-2, deoxycorticosterone (Decortin) H 12, 5mg / day).

[0099] After additional application of an aqueous ophthalmic solution containing 0.1% chitosan-NAC (modification degree: 212 μM free thiol groups / g polymer) to the eye (once a day for 7 days), the corneal epithelium Defects are cured.

[0100] Example 4 Case Study

[0101] A 31-year-old male co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a sterile aqueous ophthalmic solution comprising N-(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N-(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 [mu]mol / g polymer to 280 [mu]mol / g polymer, for use in the treatment of corneal wounds.

Description

technical field [0001] The present invention relates to the therapeutic use of a sterile ophthalmic solution comprising a carrier solution of N-(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof. Background technique [0002] Mechanical corneal injury, the most common ocular injury, is usually caused by the action of a physical force (eg, tree branches, fingernails, cosmetic applicators) that damages a minor or major portion of the corneal surface. Foreign body-related abrasions are usually caused by airborne debris (eg, metal splinters, wood chips, glass shards, etc.) embedded in the cornea. After removal of the foreign body, defects remain in the corneal epithelium. A defect in contact lens-related abrasions on the corneal epithelium resulting from excessive contact lens wearing or wearing of inappropriate accessories, or improper cleaning of contact lenses. [0003] Chemical corneal injury is another cause of corneal trauma. Exposure to alkaline...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K47/02A61K47/12A61K9/08A61K31/722
CPCA61K9/0048A61K47/02A61K47/12A61K9/08A61K31/722A61P27/02A61K31/616A61P27/00
Inventor 马丁·普林茨
Owner CROMA PHARMA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com